No Data
No Data
Shareholder Qingdao Guoyao of Yaokang Biological (688046.SH) reduced its shareholding by 0.8882 million shares, decreasing its stake to 5%.
Yao Kang Biology (688046.SH) announced that on September 24, 2024, the shareholder Qingdao National Pharmaceutical Daichuang ...
We Think That There Are More Issues For GemPharmatech (SHSE:688046) Than Just Sluggish Earnings
YaoKang Biotech (688046.SH): Cumulative repurchase of 0.3712% of the company's shares.
On September 2nd, GeLongHui announced that as of August 31st, 2024, the company has repurchased a total of 1,521,975 shares of the company through the Shanghai Stock Exchange trading system through centralized competitive bidding, accounting for 0.3712% of the company's total share capital of 410,000,000 shares. The highest repurchase price was 19.17 yuan per share, and the lowest price was 11.89 yuan per share. The total amount paid was RMB 23,862,462.57 (excluding stamp duty, transaction fees, and other trading costs).
Yakkang Biotech 2024 Semi-Annual Report
Summary of Yakkang Biotech\'s 2024 Semi-Annual Report
Yao Kang Biology (688046.SH) released its semi-annual performance, with a net income of 76.34 million yuan, a year-on-year decrease of 1.59%.
Yao Kang Biology (688046.SH) disclosed the semi-annual report for 2024, and the company achieved revenue of 0.34 billion during the reporting period...
No Data
No Data